Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Credit agrmnt [a]
Appointed director
Quarterly results
Director departure
|
|
ANGIOTECH PHARMACEUTICALS INC (ANPMF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/28/2013 |
8-K
| Quarterly results |
| 11/14/2012 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2012 Vancouver, BC, November 14, 2012 — Angiotech Pharmaceuticals, Inc. announced that it released its financial results for the third quarter ended September 30, 2012. Angiotech will host a conference call discussing its first quarter financial results on November 15, 2012 at 1:00 PM ET . Details regarding the conference call can be found on Angiotech's website at www.angiotech.com. “Our business performance in the third quarter continued to reflect exceptional efforts by our staff to turn our business around in 2012 and move it forward on a renewed path,” said Thomas Bailey, President and CEO of Angiotech. “Consistent with the first half of the year, we were able to continue our revenue growth, and our gross ..." |
|
| 08/14/2012 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2012 Vancouver, BC, — Angiotech Pharmaceuticals, Inc. announced that it released its financial results for the second quarter ended June 30, 2012. Angiotech will host a conference call discussing its first quarter financial results on August 15, 2012 at 1:00 PM ET . Details regarding the conference call can be found on Angiotech's website at www.angiotech.com. “We are extremely pleased to announce our third consecutive quarter of significantly improved financial results. Our improved revenue growth, cash flows, liquidity and profitability are a culmination of the hard work and dedication of our team following the conclusion of our restructuring and business change initiatives last year,” said Thomas Bailey, Angiote..." |
|
| 05/15/2012 |
8-K
| Form 8-K - Current report |
| 11/09/2011 |
8-K
| Form 8-K - Current report |
| 08/09/2011 |
8-K
| Quarterly results |
| 05/16/2011 |
8-K
| Form 8-K - Current report |
| 03/16/2011 |
8-K
| Quarterly results |
| 07/30/2010 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2010 Vancouver, BC, July 30, 2010 - Angiotech Pharmaceuticals, Inc. today announced its financial results for the second quarter ended June 30, 2010. “We are pleased to report continued quarter over quarter growth in product sales, driven primarily by our most innovative Proprietary Medical Products," said Dr. William Hunter, President and CEO of Angiotech. "In addition, we are encouraged by sales trends for our Base Medical Products, which continued to show steady improvement across all key product groups through the first half of 2010." Second Quarter Financial Highlights Selected Non-GAAP Financial Measures" |
|
| 05/04/2010 |
8-K
| Quarterly results |
| 03/04/2010 |
8-K
| Form 8-K - Current report |
| 11/09/2009 |
8-K
| Form 8-K - Current report |
| 08/06/2009 |
8-K
| Form 8-K - Current report |
| 04/30/2009 |
8-K
| Form 8-K -- Current report |
| 03/05/2009 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2008 Vancouver, BC, March 5, 2009 - Angiotech Pharmaceuticals, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2008. “During 2008 we achieved solid sales results in our Medical Products Business and were able to sustain progress on our most important new technology initiatives despite a challenging year for TAXUS,” said Dr. William Hunter, President and CEO of Angiotech. “Not only did we increase Medical Products sales compared to 2007, but we were able to achieve this growth while making reductions to our operating expenses. This has been a challenging year with many factors including the turmoil in the capital and credit markets impacting our..." |
|
| 11/06/2008 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2008 Vancouver, BC, November 6, 2008 - Angiotech Pharmaceuticals, Inc. , a global specialty pharmaceutical and medical device company, today announced its financial results for the third quarter ended September 30, 2008. “Our Medical Products sales results continued their growth trend in the third quarter, with solid improvement as compared to the same period in 2007,” said Dr. William Hunter, President and CEO of Angiotech. “Sales of our Promoted Brand product portfolio, including Quill™ SRS and the newly launched HemoStream™ chronic dialysis catheter, continue to show differential growth, and the cost reduction initiatives we announced have started to take hold, with reduced reported expenses across all operating categ..." |
|
| 07/28/2008 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2008 Vancouver, BC, July 28, 2008 - Angiotech Pharmaceuticals, Inc. , a global specialty pharmaceutical and medical device company, today announced its financial results for the second quarter ended June 30, 2008. “Our operating businesses continued to deliver results in the second quarter, with our Medical Products segment sales exceeding $50 million,” said Dr. William Hunter, President and CEO of Angiotech. “Our various promoted brands again exhibited strong sales performance in the quarter, and we believe that we can achieve our full year objectives for sales growth, margin improvement and new product introductions.” Significant Recent Developments On July 7, 2008, we announced that our Board of Directors authorized a tra..." |
|
| 04/29/2008 |
8-K
| Quarterly results |
|
|